Literature DB >> 11854476

HIV's response to a CCR5 inhibitor: I'd rather tighten than switch!

Joshua M Farber1, Edward A Berger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11854476      PMCID： PMC122263          DOI： 10.1073/pnas.042708299

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  14 in total

Review 1.  The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS.

Authors:  S J O'Brien; J P Moore
Journal:  Immunol Rev       Date:  2000-10       Impact factor: 12.988

2.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.

Authors:  Alexandra Trkola; Shawn E Kuhmann; Julie M Strizki; Elizabeth Maxwell; Tom Ketas; Tom Morgan; Pavel Pugach; Serena Xu; Lisa Wojcik; Jayaram Tagat; Anandan Palani; Sherry Shapiro; John W Clader; Stuart McCombie; Gregory R Reyes; Bahige M Baroudy; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

Review 3.  Mechanisms of viral membrane fusion and its inhibition.

Authors:  D M Eckert; P S Kim
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

Review 4.  HIV chemotherapy.

Authors:  D D Richman
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

Review 5.  CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2.

Authors:  J A Hoxie; C C LaBranche; M J Endres; J D Turner; J F Berson; R W Doms; T J Matthews
Journal:  J Reprod Immunol       Date:  1998-12       Impact factor: 4.054

Review 6.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.

Authors:  E A Berger; P M Murphy; J M Farber
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

7.  Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.

Authors:  D E Mosier; G R Picchio; R J Gulizia; R Sabbe; P Poignard; L Picard; R E Offord; D A Thompson; J Wilken
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

8.  Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor.

Authors:  C Cheng-Mayer; R Liu; N R Landau; L Stamatatos
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

Review 9.  Host factors and the pathogenesis of HIV-induced disease.

Authors:  A S Fauci
Journal:  Nature       Date:  1996-12-12       Impact factor: 49.962

Review 10.  Chemokine receptors and the clinical course of HIV-1 infection.

Authors:  A M de Roda Husman; H Schuitemaker
Journal:  Trends Microbiol       Date:  1998-06       Impact factor: 17.079
View more
  5 in total

1.  Persistence and emergence of X4 virus in HIV infection.

Authors:  Ariel D Weinberger; Alan S Perelson
Journal:  Math Biosci Eng       Date:  2011-04       Impact factor: 2.080

2.  Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy.

Authors:  Ruy M Ribeiro; Mette D Hazenberg; Alan S Perelson; Miles P Davenport
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Shikonin, a component of chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1.

Authors:  Xin Chen; Lu Yang; Ning Zhang; Jim A Turpin; Robert W Buckheit; Clay Osterling; Joost J Oppenheim; O M Zack Howard
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

4.  CD8+ T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques.

Authors:  Janet M Harouse; Clarisa Buckner; Agegnehu Gettie; Ross Fuller; Rudolf Bohm; James Blanchard; Cecilia Cheng-Mayer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-08       Impact factor: 11.205

5.  Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.

Authors:  Shawn E Kuhmann; Pavel Pugach; Kevin J Kunstman; Joann Taylor; Robyn L Stanfield; Amy Snyder; Julie M Strizki; Janice Riley; Bahige M Baroudy; Ian A Wilson; Bette T Korber; Steven M Wolinsky; John P Moore
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.